Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

USA: Researchers have found in a recent observational study that patients with generalized pustular psoriasis (GPP) face a ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

Pustular Psoriasis Types There are multiple types of pustular psoriasis. They fall into two broad categories, generalized or localized, depending on whether it affects a large area or is more limited.

Generalized pustular psoriasis (GPP) is a severe form of pustular psoriasis, a group of conditions known for causing breakouts of painful pus-filled lesions (pustules).

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

SPEVIGO ® is a prescription medicine used to treat generalized pustular psoriasis (GPP) in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg).

Genetic pustular psoriasis can develop due to a combination of environmental factors and genetic traits, with stress and infection as potential triggers.